FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

FibroGen Stock Down 4.0 %

FGEN opened at $0.34 on Friday. FibroGen has a twelve month low of $0.30 and a twelve month high of $2.93. The company’s 50-day moving average price is $0.39 and its two-hundred day moving average price is $0.89. The stock has a market cap of $34.13 million, a price-to-earnings ratio of -0.14 and a beta of 0.70.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09. The firm had revenue of $50.64 million for the quarter, compared to the consensus estimate of $33.00 million. During the same period last year, the company posted ($0.65) earnings per share. As a group, sell-side analysts anticipate that FibroGen will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On FibroGen

Several institutional investors have recently added to or reduced their stakes in FGEN. Accel Wealth Management purchased a new position in FibroGen in the 1st quarter valued at approximately $103,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of FibroGen during the 1st quarter valued at $131,000. Acadian Asset Management LLC lifted its holdings in FibroGen by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after purchasing an additional 34,937 shares in the last quarter. Delap Wealth Advisory LLC purchased a new stake in FibroGen during the 1st quarter worth about $27,000. Finally, Alpine Global Management LLC bought a new position in FibroGen in the 1st quarter worth about $25,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.